

K091862

**510(k) Summary**

Page 1 of 3

14-Sep-2009

PharmaCaribe  
1600 Mill Quarter Rd  
Powhatan, VA 23139

Tel (804) 339-4523  
Fax (866) 489-2738

NOV 20 2009

**Official Contact:** Werner Gutmann COO

**Proprietary or Trade Name:** NESSI Spacer

**Common/Usual Name:** Spacer / Holding Chamber

**Classification Name:** Holding Chambers, Direct Patient Interface  
NVO - CFR 868.5630

**Predicate Devices:** K010680 – CT Spacer  
K070674 – Trudell AeroChamber Plus

**Device Description:**

The NESSI is a spacer intended for use in the inhalation of MDIs for the therapy of the upper and lower respiratory system. The device consists of a translucent housing a back piece and mouth piece.

The NESSI Spacer can be used to inhale aerosolized drugs of approved MDIs from the following groups of active substances:

- Corticosteroids (anti-inflammatory medications)
- Anti-cholinergics and  $\beta$ 2-sympathomimetics (bronchodilator medications)
- Non-steroidal chromones (DNCG)

It is a single patient, multi-use device.

**Indications for Use:**

The NESSI Spacer is intended to be used by patients who are under the care of treatment of a licensed healthcare professional or physician. The device is intended to be used by these patients to administer aerosolized medication from pressurized Metered-Dose Inhalers, prescribed by a physician or healthcare professional

**Patient Population:** Any individual

**Environment of Use:** Home care, nursing homes, sub-acute institutions, and hospitals

**Contraindications:** None

**510(k) Summary**

Page 2 of 3

14-Sep-2009

Attribute	K010680	K070674	Proposed
	Clinical Technologies	Trudell Medical	PharmaCaribe
	CT Spacer	AeroChamber Plus	NESSI
Indications for Use	The CT Spacer is a spacer used with a MDI or a nebulizer to deliver inhalable drug aerosols to a patient. The spacer is to be used by a single patient, for a maximum of 28 days.	The AeroChamber Plus® a VHC with Flow-Vu® IFI is intended to be used by patients who are under the care or treatment of a licensed health care provider or physician. The device is intended to be used by these patients to administer aerosolized medication from most pressurized Metered Dose Inhalers, prescribed by a physician or health care professional. The intended environments for use include the home, hospitals and clinics.	The NESSI Spacer is intended to be used by patients who are under the care of treatment of a licensed healthcare professional or physician. The device is intended to be used by these patients to administer aerosolized medication from pressurized Metered-Dose Inhalers, prescribed by a physician or healthcare professional
Environments of use	Not specified	Home, hospitals and clinics.	Home care, nursing homes, sub-acute institutions, and hospitals
Prescriptive	Yes	Yes	Yes
Patient population	Not specified	All	All
Single patient reusable	Yes	Yes	Yes
Used with mouthpiece or face mask	Yes	Yes	Yes
Used with pressurized metered dose inhalers	Yes	Yes	Yes
Anti-static claim	No	Yes	Yes

## 510(k) Summary

Page 3 of 3

14-Sep-2009

The NESSI Spacer is viewed as substantially equivalent to the predicate devices because:

### **Indications –**

Similar to predicates - K010680 – CT Spacer and K070674 – Trudell AeroChamber Plus

### **Technology –**

Similar to predicate – K010680 – CT Spacer

### **Materials –**

The materials used are identical to those used in 510(k) K082092, with the identical exposure characteristics and we have provided ISO 10993 testing as well.

### **Environment of Use –**

Identical to K070674 – Trudell AeroChamber Plus

### **Patient Population –**

Similar to K070674 – Trudell AeroChamber Plus

### **Differences –**

The NESSI Spacer is viewed as substantially equivalent to the following predicate devices – K010680 – CT Spacer and K070674 – Trudell AeroChamber Plus.

There are no significant differences that affect the safety or effectiveness of the intended device when compared to the predicate devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room - WO66-0609  
Silver Spring, MD 20993-0002

PharmaCaribe  
C/O Mr. Paul E. Dryden  
President  
ProMedic, Incorporated  
24301 Woodsage Drive  
Bonita Springs, Florida 34134-2958

NOV 20 2009

Re: K091862  
Trade/Device Name: NESSI Spacer  
Regulation Number: 21 CFR 868.5630  
Regulation Name: Nebulizer  
Regulatory Class: II  
Product Code: NVO  
Dated: November 12, 2009  
Received: November 16, 2009

Dear Mr. Dryden:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to

<http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Susan Runner, D.D.S., M.A.

Acting Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Indications for Use Statement

Page 1 of 1

**510(k) Number:** K091862 (To be assigned)

**Device Name:** NESSI Spacer

**Indications for Use:**

The NESSI Spacer is intended to be used by patients who are under the care of treatment of a licensed healthcare professional or physician. The device is intended to be used by these patients to administer aerosolized medication from pressurized Metered-Dose Inhalers, prescribed by a physician or healthcare professional.

**Prescription Use XX**  
(Part 21 CFR 801 Subpart D)

or

**Over-the-counter use** \_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
\_\_\_\_\_  
(Division Sign-Off)  
Division of Anesthesiology, General Hospital  
Infection Control, Dental Devices

510(k) Number: K091862